Low Grade Glioma D33 D43
Conditions
Interventions
Group 1: From samples taken during the routine (tumor tissue and blood), a molecular fingerprint of the tumor is generated by DNA methylation profile and RNA sequencing. Using this data, it is possibl
Sponsors
Hopp Kindertumorzentrum Heidelberg
Eligibility
Sex/Gender
All
Age
No minimum to 20 Years
Inclusion criteria
Inclusion criteria: - Age < 21 years. - Histologically verified LGG Exceptions (i.e. MRI based diagnosis) can be accepted only where a biopsy would pose an unacceptable risk to damage of eloquent brain structures. - Primary diagnosis or at relapse/progression - At primary diagnosis: - Histologically verified low-grade glioma / glioneuronal tumour WHO grade I or II. - Fresh frozen and paraffin tumour material together with blood available for molecular diagnostics. -At relapse/progression: -Fresh frozen and paraffin tumour material together with blood available for molecular diagnostics from primary diagnosis and/or current episode (preferably) of relapse/progression. - No exceptions for the submission of fresh frozen and paraffin tumour material with blood - In case that the date of diagnosis is earlier than the start of LOGGIC Core in a country, submission of fresh frozen and paraffin tumour material together with blood is mandatory with no exceptions (in other words, one can include “retrospective cases” only if material is available). - Before patient registration, written informed consent, including data and tumour material transfer, must be given according to ICH/GCP, and national/local regulations. - Residency in one of the participating countries of LOGGIC Core.
Exclusion criteria
Exclusion criteria: No LGG
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establishment of a molecular and clinical data base for pediatric low grade glioma | — |
Secondary
| Measure | Time frame |
|---|---|
| To collect molecular tumour characteristics of LGG patients for exploratory analysis of biomarker and clinical outcome. | — |
Countries
Australia, Austria, Belgium, Czechia, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom
Contacts
Public ContactCarina Bodden
Hopp Kindertumorzentrum Heidelberg
Outcome results
None listed